I think that was an excellent move.
What BINC does is hold the patent
on a full bulk, low calorie sugar
substitute.
Dtagatose is naturally occuring in
nature and produced from whey.
It can be baked or cooked, has no
aftertaste like other sweetners and
is safe for diabetics.
Several food producers have been in
contact with MDFI, the company that
bought the rights to produce Dtag,
such as Wrigleys, Pepsi and Nestles.
Imagine diet soft drinks, candy, cookies,
etc, made with Dtagatose. The market
is many billions a year. Think of it
as Olestra, but with a much larger market.
BINC will get royalties off every pound
produced plus they still have not sold
medical rights, which are plentiful.
Dtagatose also reduces appetites and has
several other benefits.
In a year or three, assuming GRAS (generally
regarded as safe) is granted by the FDA, which
is expected any day now that the
research has been published, it would not
be unreasonable to think in terms of several
bucks a share net profit for BINC. All that,
without any of the other benefits being included.
A very wise buy, IMHO. |
